Jazz Pharmaceuticals (JAZZ) Phase 3 Trial Evaluating Nabiximols Oromucosal Spray Did Not Meet Primary Endpoint
Go back to Jazz Pharmaceuticals (JAZZ) Phase 3 Trial Evaluating Nabiximols Oromucosal Spray Did Not Meet Primary Endpoint| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 109.13 -0.54 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $109.67 | 52 Week High | $160.00 | |||
| Open | $108.66 | 52 Week Low | $95.80 | |||
| Day High | $109.39 | P/E | 20.28 | |||
| Day Low | $108.66 | EPS | $5.38 | |||
| Volume | 25,338 | |||||
